Signal-Dependent Transcription (SDT) inhibitors, as a chemical class, encompass a diverse group of compounds that share a common feature: the ability to interfere with the transcriptional processes within cells. These inhibitors are designed to modulate the intricate machinery governing gene expression, ultimately exerting control over the synthesis of specific proteins. SDT inhibitors operate at various levels of the transcriptional cascade, targeting key molecular players to disrupt or fine-tune the transcriptional output. They have garnered substantial attention in both basic research and drug development due to elucidate the intricacies of cellular regulation and pave the way for novel strategies.
At the core of SDT inhibitors' mechanisms lies their capacity to interact with pivotal molecular components involved in transcriptional control. These compounds can impact transcription factors, which are crucial proteins that bind to DNA and facilitate or inhibit the transcription of specific genes. SDT inhibitors can also target regulatory enzymes such as kinases or phosphatases that modulate the activity of transcription factors. By manipulating these molecular interactions, SDT inhibitors can either enhance or suppress gene expression, thereby influencing cell behavior. The versatility of SDT inhibitors makes them valuable tools in the exploration of cellular processes, allowing researchers to dissect the roles of individual genes and pathways. Their applications extend beyond encompassing areas like gene regulation studies, cellular signaling research, and the development of molecular probes for dissecting intricate biological processes. In summary, SDT inhibitors constitute a chemically diverse class of compounds that hold promise not only for interventions but also for advancing our fundamental understanding of gene expression and cellular regulation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen is a selective estrogen receptor modulator (SERM) that competes with estrogen for binding to the estrogen receptor. It inhibits estrogen-dependent transcription, particularly in breast cancer cells. | ||||||
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $83.00 $187.00 | 34 | |
ICI 182,780, also known as Fulvestrant, is a pure antiestrogen that acts as an estrogen receptor antagonist, leading to receptor degradation. This disrupts estrogen signaling and transcriptional activity. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Enzalutamide is an androgen receptor antagonist that blocks the binding of androgens to their receptor. This inhibits androgen-dependent transcription in prostate cancer cells. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene is another SERM that interferes with estrogen receptor function. It selectively modulates estrogen-dependent transcription in various tissues. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). By inhibiting EGFR signaling, it suppresses downstream transcriptional events in cancer cells. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Erlotinib is another EGFR inhibitor that works similarly to Gefitinib, blocking EGFR-driven transcription by interfering with receptor phosphorylation and downstream signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF and VEGF receptors. By inhibiting these kinases, it disrupts signaling pathways that regulate transcription and angiogenesis in cancer. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits BCR-ABL and other tyrosine kinases involved in chronic myeloid leukemia (CML). By blocking kinase activity, it halts the abnormal transcription and proliferation of CML cells. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that interferes with the MAPK signaling pathway. It reduces the phosphorylation of transcription factors, limiting their activation and downstream gene expression. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used in B-cell malignancies. It hinders BTK signaling, which is crucial for B-cell receptor-mediated transcription and survival. | ||||||